Athena Bioscience, LLC yakazivisa hurongwa hwekutanga kutengeserana kweNexiclon XR, iyo chete pazuva-zuva nezuva clonidine yakawedzerwa-kuburitswa mahwendefa anoratidzwa kurapwa kwehypertension.1 Athena akawana kodzero dzakakwana dzekutengesa chigadzirwa kubva kuTris Pharma, Inc. muna Kukadzi 2021. The kutanga kwakagadzwa muna Kubvumbi 2022 mumatunhu makumi mashanu ese eUS.
Paavhareji, 50% chete yevanhu vakuru vanoomerera kumishonga yechirwere chechirwere chisingaperi2, uye munyaya yehutano hwepamusoro (BP), mazinga akaderera ekuomerera akabatanidzwa neBP yakaipisisa uye migumisiro yakaipa, kusanganisira sitiroko, myocardial infarction, kukanganisa kwemwoyo, uye rufu.3-5 Nexiclon XR inopa zvakafanana antihypertensive kliniki inobatsira yekukurumidza-kusunungurwa clonidine mune yakanakira, kamwe-zuva piritsi.6
"Tinotenda kuti kuve nyore kwepiritsi kamwe-zuva kunogona kubatsira mukuwedzera kuomerera kwemurwere kuhurongwa hwemishonga," akadaro Jeff Bryant, CEO weAthena. "Kuteerera kurinani kunofanirwa kupa mhedzisiro yekurapa kune avo vanorwara nehypertension."
"Kutangwa kweNexiclon XR kunoratidza Tris 'kuenderera mberi nekubudirira kuunza akasiyana tekinoroji-based mishonga kumusika," akadaro Tris CEO Ketan Mehta. "Tichifunga nezve rekodhi yavo yakasimbiswa, isu tinofara kuti Athena ndiye shamwari yedu, kutanga ichi chakakosha chemoyo chigadzirwa." Nexiclon yakavakirwa paTris's LiquiXR® yekuendesa zvinodhaka tekinoroji, izvo zvakakonzera kugadzirwa kweakawanda ekutanga-mu-chikamu zvigadzirwa.
ZVOKUBVA MUNYAYA INO:
- On average, only 50% of adults adhere to chronic disease medications2, and in the case of high blood pressure (BP), lower levels of adherence are associated with worse BP control and adverse outcomes, including stroke, myocardial infarction, heart failure, and death.
- “We believe the convenience of a once-daily tablet can contribute to increased patient adherence to medication regimens,”.
- The launch is set for April 2022 in all 50 U.
